Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CUMBERLAND PHARMACEUTICALS INC
Report date May 31, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,618 |
Reported balance
After 2022-05-31 transaction · row 1
1 source rowRow 1 · 2022-05-31 · Other · Disposed 33,500 · Balance 129,618 F1: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2021-03-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2032-03-16 | Direct | 0 |
Reported balance
After 2022-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-16 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement. |
Filing footnotes · ownership attribution and instrument terms
F1: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2022 Filed Jul 1, 2022 19:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 33,500 | $2.09 | $70,015.00 |
DisclosureSEC source: 0001209191-22-040113 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,618 F1 · kind: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement. Read SEC document |
| March 16, 2022 Filed Apr 29, 2022 17:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-22-026150 · doc4.xml · derivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-03-16 F1 · derivative.exercise_date: 100% vesting on March 16, 2026. Read SEC document |
| March 16, 2022 Filed Jul 1, 2022 19:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Disposition to issuerOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-22-040113 · doc4.xml · derivative · entry 3 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2032-03-16 F1 · shares: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement. Read SEC document |
| March 17, 2021 Filed Jun 11, 2021 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-039925 · doc4.xml · derivative · entry 2 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F2 · derivative.exercise_date: 100% vesting on March 17, 2025. Read SEC document |
| March 17, 2021 Filed Jun 11, 2021 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 2,870 | $3.22 | $9,241.40 |
DisclosureSEC source: 0001209191-21-039925 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,118 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 17, 2021 Filed Jul 1, 2022 19:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Disposition to issuerOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-040113 · doc4.xml · derivative · entry 2 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F1 · shares: Retired from position as Executive Vice President, Chief Development & Operations Officer on May 31, 2022. All unvested equity awards forfeited upon retirement. Read SEC document |
| March 23, 2020 Filed Apr 17, 2020 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 25,000 | $3.56 | $89,000.00 |
DisclosureSEC source: 0001209191-20-024873 · doc4.xml · nonDerivative · entry 2 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,988 F2 · shares: Restricted stock award will vest 100% on March 23, 2024. Read SEC document |
| March 18, 2020 Filed Apr 17, 2020 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 9,637 | $3.53 | $34,018.61 |
DisclosureSEC source: 0001209191-20-024873 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,988 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 22:24 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 3,710 | $4.93 | $18,290.30 |
DisclosureSEC source: 0001209191-19-058440 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,051 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| August 26, 2019 Filed Aug 30, 2019 21:20 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,850 | $5.63 | $10,415.50 |
DisclosureSEC source: 0001209191-19-047852 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,761 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| May 21, 2019 Filed May 31, 2019 21:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,850 | $6.30 | $11,655.00 |
DisclosureSEC source: 0001209191-19-033697 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,611 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 2,343 | $5.62 | $13,167.66 |
DisclosureSEC source: 0001209191-19-021049 · doc4.xml · nonDerivative · entry 2 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,461 F2 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:22 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 25,000 | $5.98 | $149,500.00 |
DisclosureSEC source: 0001209191-19-021049 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,804 F1 · shares: Restricted stock award will vest 100% on March 18, 2023. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:45 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 2,557 | $6.70 | $17,131.90 |
DisclosureSEC source: 0001209191-18-021483 · doc4.xml · nonDerivative · entry 2 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,304 F2 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:45 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 25,000 | $6.70 | $167,500.00 |
DisclosureSEC source: 0001209191-18-021483 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,861 F1 · shares: Restricted stock award will vest 100% on March 20, 2022. Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 20:53 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 3,582 | $6.45 | $23,103.90 |
DisclosureSEC source: 0001209191-17-026299 · doc4.xml · nonDerivative · entry 2 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,861 F2 · shares: This transaction represents shares withheld by the Company to cover the tax withholding obligations for the vesting of 10,000 shares during March 2017. Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 20:53 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 10,000 | $6.45 | $64,500.00 |
DisclosureSEC source: 0001209191-17-026299 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,443 F1 · shares: Restricted stock award will vest 100% on March 17, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.